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Abstract
Objectives. To investigate the long term persistence of rituximab (RTX) in a large observational RA cohort,
investigate persistence of RTX when used as a first or second line biologic DMARD (bDMARD), to char-
acterize subsequent bDMARD treatment following RTX.
Methods. Patients with RA starting treatment with RTX (MabThera) between 2008 and 2011 were re-
cruited into the British Society for Rheumatology Biologics Register for RA. Duration of RTX treatment over
the first 4 years after initiation was estimated via Kaplan-Meier estimates and the reason for discontinu-
ation was ascertained. Subsequent bDMARD use following RTX discontinuation was characterised.
Treatment survival in bDMARD-naı¨ve (first line RTX use) and experienced (second line RTX use) cohorts
was described.
Results. One thousand six hundred and twenty-nine patients were recruited (1371 bDMARD-experienced
and 258 bDMARD-naı¨ve). Sixty percent of the whole cohort remained on RTX after 4 years. Ineffectiveness
(46%) and death (24%) were the most common reason for RTX discontinuation. RTX discontinuation was
associated with RF negativity for the bDMARD-experienced cohort. Of those that discontinued RTX, 46%
initiated treatment with another bDMARD, with tocilizumab being the most common.
Conclusion. This large study of patients initiating RTX treatment for severe RA found that 60% persisted
with treatment after 4 years. This study also identified that RTX is tolerated well when used as a first or
second line bDMARD.
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Rheumatology key messages
. The majority of patients with RA treated with rituximab remain on treatment after four years.
. The three most common reasons for rituximab discontinuation in RA were ineffectiveness, death and adverse
events.
. Rituximab is well tolerated when used as a first or second line biologic DMARD for RA.
Introduction
Medication continuation rates are a good proxy measure-
ment of treatment effectiveness and safety. Analysis of
long term continuation of a number of biologic DMARDs
(bDMARDs) in RA and identification of factors related to
drug survival has previously highlighted important clinical
trends and variations of response not initially identified in
clinical trials [15]. In 2007 approval was given for the use
of rituximab (RTX), an anti-CD20 mAb, in combination with
MTX for the treatment of patients with severe active RA
who have not adequately responded to TNF inhibitors
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(TNFi) [6]. The long term use of RTX treatment has not
been investigated as widely as other bDMARD agents;
this is primarily due to long term treatment data only
now becoming available 10 years after the approval of
RTX use. The distinct method and frequency of adminis-
tration, wide variability of dosing intervals [7] and difficulty
in capturing a discontinuation reason in research settings
[8] has also limited research into long term continuation
of RTX.
Only a small number of studies have investigated the
long term continuation of RTX use and findings are vari-
able [912]; further, the differing definitions of RTX discon-
tinuation in previous studies hinders direct comparison. In
part this relates to the challenges of defining treatment
stop dates for an irregularly dosed therapy such as RTX.
However, information on the long term continuation of
RTX in RA may aid in managing patient and clinician ex-
pectations and the planning of future treatment options on
an individual and population level.
Although use of RTX was approved for use in those who
have not adequately responded to a TNFi agent, clinical
practice sees a number of patients treated with RTX as
their first bDMARD, usually due to the presence of comor-
bidities that preclude TNFi use. Results of long term con-
tinuation with RTX when used as a first line bDMARD in this
distinct patient group has not been previously reported.
Therefore, using data from the British Society of
Rheumatology Biologics Register for RA (BSRBR-RA),
this study aims to characterize the long term use of
RTX, identify reasons for treatment discontinuation, iden-
tify factors associated with treatment discontinuation and
characterise subsequent bDMARD use in both bDMARD-
naive and bDMARD-experienced cohorts.
Methods
Study population
Since 2001, the BSRBR-RA has collected prospective ob-
servational data on UK individuals with a rheumatologist
diagnosis of RA starting treatment with bDMARD thera-
pies with the aim of studying long-term clinical effective-
ness and safety. Between 2008 and 2011, a cohort of
patients commencing RTX was recruited. This included
patients already registered with the BSRBR-RA for previ-
ous bDMARD therapy, primarily TNFi, who re-registered
at the point of starting RTX as well as those new to the
study. UK guidelines recommended RTX be prescribed, in
combination with MTX, as two 1 gram infusions 2 weeks
apart, with at least 6 months between doses, in patients
who had failed treatment with TNFi [6]. MabThera (pro-
duced by Roche) was the only brand of RTX used
during the study period.
For patients who were new to the BSRBR-RA, the con-
sultant responsible for care was asked to complete a
baseline questionnaire that collected data on the patient’s
demographic characteristics, DAS-28 and its individual
components (at the time RTX was started), comorbidities
(from a tick list), previous and current conventional syn-
thetic DMARDs (csDMARD) and prior bDMARD exposure,
RF and smoking status. For patients already registered
with the BSRBR-RA after receiving another bDMARD,
the consultant was asked to complete a BSRBR-RA
Short Baseline Form that collected data on DAS28 at
the time RTX was started, current drug therapy and an
updated list of comorbidities. The other patient demo-
graphic characteristics and details of prior bDMARDs
were obtained from the patient’s initial registration with
the BSRBR-RA. All patients were asked to complete a
HAQ [13] at the point of starting RTX.
Follow-up data were captured from the hospital
6 monthly for 3 years and then annually thereafter. This
data included details of further RTX therapy (dates of in-
fusions) and/or discontinuation with reason: adverse
event, ineffectiveness, remission, new bDMARD therapy,
and adverse events. In addition, all patients were flagged
with the cancer and death data linkage organisations in
England, Wales, Scotland and Northern Ireland. In the
case of death, the date and cause of death were for-
warded to the study office. No data on lymphocyte
levels were captured.
Ethical approval for the BSRBR-RA was granted by the
North West Multicentre Research Ethics Committee in
2000. Written informed consent was gained at the time
of registration into the BSRBR-RA cohort. No additional
ethical approval or consent was required for this study.
Data analysis
This analysis included all patients with RA registered at
the point of starting RTX between February 2008 and
December 2011 and included all follow-up data available
to 30 November 2014. Patients were analysed as a whole
group and also divided into two cohorts based on prior
bDMARD exposure (bDMARD-experienced and bDMA
RD-naı¨ve). Baseline data were compared between those
with and without past bDMARD exposure using descrip-
tive statistics.
All patients were considered to have continuous RTX
use for 9 months (275 days) following each infusion/treat-
ment course unless they started an alternative bDMARD,
where the time of subsequent bDMARD initiation was
defined as the stop date. For example, a patient who
received a single course of RTX would be considered to
have persisted with RTX for 9 months. This 9 month time
frame was chosen to reflect the previously reported aver-
age time taken for B cell reconstitution to take place [14].
If a subsequent RTX infusion was received before the end
of this 9 month period, a further 9 months would be added
to the time on drug from the date of the subsequent infu-
sion. As the length of B cell reconstitution is variable, for
patients who received a further dose of RTX after the
9 month window, we did consider this continuous treat-
ment. For this we allowed up to 15 months as long as an
alternative bDMARD was not administered in the interval.
Persistence with RTX was described using Kaplan-Meier
survival analysis with estimates calculated at 1, 2, 3 and 4
years. Patients were censored at the time of death if it
occurred within the 9 month period following last infusion.
Each patient was recorded as having discontinued RTX
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treatment for one of the following reasons: ineffective-
ness, adverse event, remission.
Baseline variables associated with RTX persistence
were assessed using multivariable Cox-proportional haz-
ards models; the models were developed via a stepwise
backwards variable selection method. Investigated vari-
ables included demographic factors at baseline (gender,
age, smoking status), RA-specific variables (DAS-28, dis-
ease duration, RF status, HAQ score), concurrent and
past treatment (baseline glucocorticoid use, baseline
MTX, number of past bDMARDs) and the total number
of the following comorbidities as recorded on the baseline
form: hypertension, physician reported interstitial lung dis-
ease (ILD), previous cancer, angina, previous myocardial
infarction, previous stroke, epilepsy, asthma, chronic ob-
structive pulmonary disease, peptic ulcer disease, history
of liver or renal impairment, multiple sclerosis, diabetes
mellitus and depression. To avoid collinearity, two multi-
variable models were formed—one with the composite
DAS28 score along with the other investigated variables,
then a second model with the components of the DAS28
(tender joint count, swollen joint count, global health visual
analogue score, ESR) along with the other investigated
variables. Missing data were generated via multiple imput-
ation [15]; this was carried out for all variables where miss-
ing data were present The statistical program R was used
for all analysis [16].
The proportion of the cohort that initiated a subsequent
bDMARD following RTX discontinuation at any point over
the observed follow-up was calculated for both the
bDMARD-naive and experienced cohorts.
Results
Study population
In total, 1629 patients were registered with the BSRBR-RA
at the point of starting RTX, including 1371 (84%)
bDMARD-experienced patients and 258 (16%) bDM
ARD-naive (Table 1). The median age of the population
was 60 years [interquartile range (IQR): 5268) and 76%
were female. Only 68% of the cohort were reported to be
RF positive (missing in 13%). Disease severity was high
with a median baseline DAS28 score of 6.1 (IQR: 5.46.8)
and median baseline HAQ score of 2.0 (IQR: 1.62.4). A
majority of patients started RTX in combination only
alongside MTX (64%), 2% only alongside LEF and 1%
only alongside either only SSZ or HCQ. Twenty-three per-
cent initiated RTX alongside MTX and one or more
csDMARD. Ten percent of the cohort started RTX without
a csDMARD. A majority of the bDMARD-experienced
cohort started RTX after failing a single bDMARD (75%)
and all but 15 patients had received a prior TNFi (the ma-
jority etanercept or adalimumab) (Table 2). Previous
bDMARD data were not available for 93 (6.8%) of the
bDMARD-experienced cohort. bDMARD-naı¨ve patients
were significantly older, more likely to be male, had
shorter disease duration and lower HAQ scores than the
bDMARD-experienced patients (Table 1). Although
number of comorbidities was similar between each
cohort, there were differences in the occurrence of indi-
vidual comorbidities. In particular, a higher proportion of
the bDMARD-naive cohort had either ILD or previous
cancer. Ninety-five percent of the cohort received the rec-
ommended dose of RTX (two 1 gram infusions 14 days
apart).
Long-term persistence with RTX
Seven thousand two hundred and eighty-six years of
follow up data were available with a median follow up
time of 4.5 years (IQR 3.6, 5.4). An estimated 60% (95%
CI: 57%, 63%) of the whole cohort continued RTX after
4 years (Table 3). The RTX continuation estimate after
4 years was higher for the bDMARD-naive cohort, com-
pared with the bDMARD-experienced cohort: 65% (95%
CI: 59%, 72%) and 59% (95% CI: 56%, 62%), respect-
ively (Fig. 1) although the general pattern of continuation
was similar. Over the course of follow-up, the median
number of RTX treatment courses was equal in each
cohort: 3 (IQR 24). One quarter of patients only received
a single course of RTX and then discontinued and almost
50% only received two courses.
Reasons for RTX discontinuation
For the whole cohort, the most common reason for RTX
discontinuation was ineffectiveness (46%). One hundred
and thirty-seven patients died following RTX and this con-
stituted 24% of the total reasons for discontinuation.
Death was the most common reason for RTX discontinu-
ation in the bDMARD-naı¨ve cohort (33% of reasons for
RTX discontinuation) while ineffectiveness was the most
common reason in the bDMARD-experienced cohort
(50% of reasons for RTX discontinuation). A higher pro-
portion of the bDMARD-naı¨ve cohort died, compared with
the bDMARD-experienced cohort: 14 vs 7.4%, respect-
ively (2 P 4 0.01). Remission constituted only 1.2% of
the discontinuation reasons in the whole cohort. The
reason for RTX discontinuation was not identified in
12% of the whole cohort.
Factors associated with RTX discontinuation
For the whole cohort as well as a model limited to
bDMARD-experienced patients, multivariable analysis re-
vealed that RTX discontinuation was only associated with
RF negativity [whole cohort hazard ratio (HR) = 0.74 (95%
CI: 0.64, 0.87)]. Previous bDMARD use was not signifi-
cantly associated with RTX discontinuation. A model lim-
ited to bDMARD-naı¨ve patients did not identify any
independent variables associated with RTX discontinu-
ation although the sample size was small.
Subsequent bDMARD use
Of those that discontinued RTX within 4 years due to rea-
sons other than death, 263 (61%) subsequently initiated
treatment with a different bDMARD (Table 4). A signifi-
cantly higher proportion of the bDMARD-experienced
cohort was treated with a subsequent bDMARD, com-
pared with the bDMARD-naı¨ve group (2 P= 0.01). The
median time to first subsequent bDMARD following the
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last RTX dose was 1.5 years (IQR: 0.92.5) for the whole
cohort, 2 years (IQR: 1.23.1) for the bDMARD-naı¨ve
cohort and 1.5 years (IQR: 0.92.5) for the bDMARD-
experienced cohort. Tocilizumab was the most commonly
used subsequent bDMARD in each cohort.
Discussion
This study has described long term use of RTX in a large
cohort of patients with RA in routine clinical practice,
demonstrating that 60% of patients continued RTX after
4 years and that continuation was higher for patients who
were RF positive. Reasons for RTX discontinuation and
subsequent bDMARD use were also characterized, with
the most common reason for stopping being ineffective-
ness and secondly death of the patient, consistent with
previous reports [9, 17]. One quarter of patients who com-
menced RTX only received a single course of treatment
and almost one half only received two courses, suggest-
ing decisions to not persist with RTX are made early in the
course of treatment.
TABLE 1 Baseline characteristics of entire RTX cohort, bDMARD-experienced and bDMARD-naı¨ve cohorts
Variable Total cohort
bDMARD-
naı¨ve
patients
bDMARD-
experienced
patients P-valuea
Missing
data, n (%)
N 1629 258 1371
Age at RTX initiation, median (IQR), years 60.8 (51.867.9) 64.2 (56.070.6) 60.2 (51.267.6) <0.01 0
Female, n (%) 1243 (76) 174 (67) 1069 (78) <0.01 0
Smoking status <0.01 33 (2.0)
Never, n (%) 599 (37) 87 (34) 512 (37)
Previously, n (%) 644 (40) 114 (44) 530 (39)
Current, n (%) 354 (22) 56 (22) 298 (22)
Comorbidities, n (%) 0.66 0
0 612 (38) 102 (40) 510 (37)
1 518 (32) 77 (30) 441 (32)
2 326 (10) 54 (21) 272 (20)
3+ 173 (11) 25 (9.7) 148 (11)
ILD, n (%) 91 (5.6) 47 (18) 44 (3.2) <0.01 0
Previous TB, n (%) 64 (3.9) 10 (3.9) 54 (3.9) 0.99 0
Previous cancer, n (%) 215 (13) 81 (31) 134 (9.8) <0.01 0
Disease duration, median (IQR), years 12 (620) 10 (420) 13 (720) <0.01 24 (1.5)
Swollen joint count,b median (IQR) 8 (411) 8 (511) 8 (411) 0.19 25 (1.5)
Tender joint count,b median (IQR) 13 (820) 13 (820) 13 (820) 0.74 28 (1.7)
Global health VAS, median (IQR) 71 (5682) 70 (5580) 72 (5682) 0.42 35 (2.1)
ESR, median (IQR), mm/h 36 (2062) 38 (2060) 35 (2063) 0.48 337 (21)
DAS28, median (IQR) 6.1 (5.46.8) 6.1 (5.56.7) 6.1 (5.46.9) 0.99 5 (0.3)
HAQ, median (IQR) 2.0 (1.62.4) 1.9 (1.52.3) 2.1 (1.62.4) <0.01 215 (13)
Baseline oral glucocorticoid, n (%) 670 (41) 123 (48) 547 (40) 0.02 0
RF positive, n (%) 953 (68) 175 (68) 778 (57) 0.89 218 (13)
Concurrent MTX, n (%) 1043 (62) 137 (53) 906 (66) 0.01 0
Concurrent LEF, n (%) 129 (7.9) 27 (11) 102 (7.4) 0.12 0
No concurrent DMARD, n (%) 167 (10) 11 (4.3) 156 (11) <0.01 0
abDMARD-naı¨ve vs bDMARD-experienced—continuous variables compared using Wilcoxon-signed rank test and proportions
compared using Chi-squared. bOut of the 28 joints as measured in the DAS28. bDMARD: biologic DMARD; RTX: rituximab;
IQR: inter-quartile range; ILD: interstitial lung disease; TB: tuberculosis; VAS: visual analogue score; DAS28: Disease Activity
Score 28.
TABLE 2 Number and names of previous bDMARDs in the
bDMARD-experienced cohort
variable n (%)
Number of previous bDMARDs
1 1029 (75)
2 222 (16)
3+ 27 (2.0)
Unknown 93 (6.8)
Previous bDMARD
Etanercept 652 (51)a
Adalimumab 558 (44)a
Infliximab 302 (24)a
Certolizumab 23 (1.8)a
Tocilizumab 5 (0.4)a
Anakinra 6 (0.5)a
Abatacept 3 (0.2)a
Ocrelizumab 3 (0.2)a
aProportion of cohort that had been previously treated with
bDMARD. bDMARD: biologic DMARD.
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Fifty-nine percent of the bDMARD-experienced cohort
continued RTX after 4 years, indicating a high degree of
effectiveness and tolerability as a second line bDMARD.
Our continuation rates are similar to reported figures in
other studies 85% after 1 year by Harrold et al. [18],
70% continuation after 3 years by Richter et al. [11] and
50% after 4 years by De Keyser et al. [9].
Our study’s continuation rates indicate that RTX, as a
second line bDMARD, appears to be better tolerated than
second line TNFi agents, as reported in other studies. A
study of 235 Danish patients with RA revealed that after 1
year only 65% of the cohort continued a second line
bDMARD [1], which is lower than the 89% continuing
RTX after 1 year in our study. Further, a study by
Gomez-Reino et al. [19] estimated that after 2 years,
60% of patients continued a second line TNFi for treat-
ment of chronic arthritis (including RA, AS and PsA), lower
than the 76% continuing RTX after 2 years in our study. It
FIG. 1 Kaplan-Meier plot of RTX continuation after 4 years in the bDMARD-experienced and naı¨ve cohorts
bDMARD: biologic DMARD; RTX: rituximab.
TABLE 3 Proportion of patients remaining on RTX up to 4 years with discontinuation reason and subsequent biologic
initiation
variable
Whole cohort,
n=1629
bDMARD-naı¨ve
patients, n=258
bDMARD-experienced
patients, n=1371
No. of RTX courses (%)
1 383 (24) 63 (24) 320 (23)
2 355 (22) 54 (21) 301 (22)
3+ 891 (55) 141 (55) 750 (55)
Kaplan-Meier estimate after each year % (95% CI)
1 89 (87, 90) 92 (88, 95) 88 (86, 90)
2 76 (74, 78) 82 (77, 87) 75 (72, 77)
3 67 (65, 70) 73 (67, 79) 66 (64, 69)
4 60 (57, 63) 65 (59, 72) 59 (56, 62)
Reported reason for discontinuation (presented as % of all stop reasons)
Ineffectiveness, n (%) 260 (46) 30 (28) 230 (50)
Death, n (%) 137 (24) 36 (33) 101 (22)
Adverse event, n (%) 95 (17) 14 (13) 81 (18)
Remission, n (%) 7 (1) 3 (3) 4 (1)
Unknown, n (%) 68 (12) 25 (23) 43 (9)
bDMARD: biologic DMARD; RTX: rituximab.
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is therefore plausible that treatment with RTX may be a
more appropriate option following failure of the first TNFi
in selected patients, rather than treatment with an alter-
native TNFi, although understanding the reason for dis-
continuation may alter this.
The only baseline variable found to be associated with
long-term RTX continuation was RF status. The relation-
ship between RF status and response/continuation of RTX
has been identified in previous work within the BSRBR-RA
cohort, where greater response to RTX after 6 months
was seen in those who were RF positive [20]. The finding
that RF status was the only baseline variable associated
with continuation indicates that prediction of an individual
patient’s chance of continuing RTX long term may be
challenging.
This study also described the treatment persistence in
patients who are bDMARD naı¨ve at the time of starting
RTX. Although not licensed for this indication, there
were 258 patients enrolled in our study receiving RTX as
a first line bDMARD. Many of these patients had a relative
contraindication for TNFi, such as prior cancer or ILD,
which may explain why they had not received a TNFi
first. Within this cohort, 66% were still receiving RTX
after 4 years, supporting that this may be an effective
treatment option for patients where TNFi cannot be given.
A notable finding of this study was the higher proportion
of the bDMARD-naı¨ve cohort that had died after 4 years,
compared with the bDMARD-experienced cohort: 14 vs
7%, respectively. This difference may reflect the older age
and higher comorbidity burden in the bDMARD-naı¨ve
cohort, the latter which may have been the reason RTX
was chosen as a first line bDMARD.
Tocilizumab was the most common subsequent
bDMARD used in our cohort. The predominant use of
this agent following RTX discontinuation has been re-
ported previously [21] and is likely due to many factors,
including the dates of availability of the various treatment
options and also the fact that many patients had already
failed more than one TNFi prior to starting RTX. That the
bDMARD naı¨ve patients were also less likely to receive a
TNFi following RTX also supports that this group likely
continued to have contraindications to TNFi.
Strengths
The large size of this study cohort and the availability of
long-term follow up data are major strengths; the inclusion
of a bDMARD naı¨ve cohort also for the first time describes
outcomes in patients within this treatment history. A fur-
ther strength is the accurate capture of all cancer diag-
noses and deaths through linkage of the cohort to
corresponding national registers.
Limitations
The level of missing data is a weakness of this study; for
example, RF status was missing in 13% of the cohort. The
absence of data on anti-CCP positivity prohibited investi-
gation into its relationship with RTX discontinuation.
Ascertaining an RTX discontinuation reason presented a
challenge as only one reason for RTX discontinuation was
recorded, even though the decision to discontinue treat-
ment may have been multifactorial.
Conclusions
This study of a large cohort of patients initiating RTX treat-
ment for severe RA highlighted that 60% persisted with
treatment after 4 years. This study also identified that RTX
is also tolerated well when used as first line bDMARD.
These findings should be of value to clinicians when se-
lecting a first or second line bDMARD for patients with RA.
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